GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » ROC %

Sequenom (Sequenom) ROC % : -73.51% (As of Jun. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Sequenom ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sequenom's annualized return on capital (ROC %) for the quarter that ended in Jun. 2016 was -73.51%.

As of today (2024-04-25), Sequenom's WACC % is 0.00%. Sequenom's ROC % is 0.00% (calculated using TTM income statement data). Sequenom earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Sequenom ROC % Historical Data

The historical data trend for Sequenom's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequenom ROC % Chart

Sequenom Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -220.51 -221.04 -168.16 -14.22 -16.36

Sequenom Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.22 -85.69 -126.67 -159.89 -73.51

Sequenom ROC % Calculation

Sequenom's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2015 is calculated as:

ROC % (A: Dec. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2014 ) + Invested Capital (A: Dec. 2015 ))/ count )
=-7.881 * ( 1 - -1.52% )/( (67.14 + 30.688)/ 2 )
=-8.0007912/48.914
=-16.36 %

where

Sequenom's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2016 is calculated as:

ROC % (Q: Jun. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2016 ) + Invested Capital (Q: Jun. 2016 ))/ count )
=-17.824 * ( 1 - -0.91% )/( (26.544 + 22.393)/ 2 )
=-17.9861984/24.4685
=-73.51 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2016) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequenom  (NAS:SQNM) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sequenom's WACC % is 0.00%. Sequenom's ROC % is 0.00% (calculated using TTM income statement data). Sequenom earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Sequenom ROC % Related Terms

Thank you for viewing the detailed overview of Sequenom's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequenom (Sequenom) Business Description

Traded in Other Exchanges
N/A
Address
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
Executives
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler director
Charles P Slacik director 250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton officer: Sr VP, GC & Secretary 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver officer: SVP & CFO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas director
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii director, officer: Chairman, President & Sec 22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg director, officer: EVP and Treasurer P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis director REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch officer: President & CEO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Sequenom (Sequenom) Headlines

From GuruFocus

Context Capital Management's Top Buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-15-2015

Sequenom Inc. CEO Harry Hixson Bought 50,000 Shares

By GuruFocus GuruFocus 08-03-2012

Gurus Hold Five-Year Lows in Biotech, Utilities

By Sally Jones Sally Jones 09-20-2013

Sequenom Officer Acquires 30,000 Shares

By Jennifer Chiou Jennifer Chiou 05-10-2016

Sequenom Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010